Full TitleCDX1140-01: A Phase 1 Study of CDX-1140, a Fully Human Agonist anti-CD40 Monoclonal Antibody, as Monotherapy or in Combination in Patients with Advanced Malignancies
The purpose of this study is to find the highest dose of the investigational immunotherapy drug CDX-1140 that can be given safely in patients with advanced solid tumors that have continued to grow despite prior treatment. CDX-1140 is designed to boost the immune response against cancer by targeting a protein on immune cells called CD40. Other studies have shown that drugs like CDX-1140 can trigger the immune system to help fight cancer. CDX-1140 is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have an advanced solid tumor that has come back or continued to grow despite treatment, including one of the following: melanoma (skin or eye), bladder/urothelial, non-small cell lung cancer, pancreatic, breast, colorectal, gastric (stomach), esophageal, renal cell (kidney), hepatic (liver), ovarian, head and neck, or bile duct cancer (cholangiocarcinoma).
- Patients should recover from the serious side effects of prior therapies before entering the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Danny Khalil at 646-888-4384.